Agapurin Sr 600

Leaflet attached to the packaging: information for the user

Warning! The leaflet should be kept. Information on the immediate packaging in a foreign language.

AGAPURIN SR 600 (АГАПУРИН SR 600)

600 mg, prolonged-release tablets

Pentoxifylline
AGAPURIN SR 600 and АГАПУРИН SR 600 are the same trade names for the same drug, written in Polish and Bulgarian.

You should carefully read the contents of the leaflet before taking the medicine, as it contains important information for the patient.

• You should keep this leaflet, so that you can read it again if you need to.
• If you have any doubts, you should consult a doctor or pharmacist.
• This medicine has been prescribed to you specifically. Do not pass it on to others. The medicine may harm another person, even if their symptoms are the same.
• If the patient experiences any side effects, including any side effects not listed in this leaflet, they should tell their doctor, pharmacist, or nurse. See section 4.

Table of contents of the leaflet:

• 1. What is Agapurin SR 600 and what is it used for
• 2. Important information before taking Agapurin SR 600
• 3. How to take Agapurin SR 600
• 4. Possible side effects
• 5. How to store Agapurin SR 600
• 6. Contents of the packaging and other information

1. What is Agapurin SR 600 and what is it used for

Indications for use of Agapurin SR 600:

• peripheral arterial and arteriovenous circulatory disorders caused by atherosclerosis, diabetes, as well as disorders of inflammatory or functional origin; intermittent claudication or rest pain, diabetic angiopathy, atherosclerotic disease of the arteries, trophic changes (post-thrombotic syndrome, leg ulcers, gangrene), angioneuropathies;
• circulatory disorders in the eye (acute and chronic circulatory disorders in the retina and choroid);
• disorders of the inner ear (hearing disorders, sudden hearing loss, etc.) caused by circulatory disorders;
• brain hypoxia (post-stroke conditions, cerebrovascular disorders with symptoms such as lack of concentration, dizziness, memory disorders, etc.).

Agapurin SR 600 is intended for use in adult patients.

2. Important information before taking Agapurin SR 600

When not to take Agapurin SR 600

Warnings and precautions

Before starting treatment with Agapurin SR 600, you should discuss it with your doctor or pharmacist.
The doctor should consider the benefit-to-risk ratio of using Agapurin SR 600 in patients with arterial hypotension, severe heart rhythm disorders, advanced coronary and cerebral atherosclerosis, recent myocardial infarction, diabetes, and severe renal impairment.
If symptoms of anaphylactic or pseudo-anaphylactic reactions occur, you should stop taking Agapurin SR 600 and immediately contact your doctor.
During treatment with Agapurin SR 600, patients with severe heart rhythm disorders, advanced coronary and cerebral atherosclerosis, and hypotension after myocardial infarction should be under constant medical supervision.
Renal impairment (creatinine clearance <30 ml min) and severe liver impairment may cause delayed elimination of pentoxifylline. in such cases, the dose medicine should be reduced, patient under constant medical supervision.
Patients with an increased tendency to bleeding, taking Agapurin SR 600 simultaneously with vitamin K antagonists, platelet aggregation inhibitors, or oral antidiabetic drugs, should be under constant medical supervision.
Patients taking Agapurin SR 600 simultaneously with oral antidiabetic drugs should be under constant medical supervision (see "Agapurin SR 600 and other medicines" below).
In patients with low blood pressure or heart disease, after administration of Agapurin SR 600, a sudden drop in blood pressure and, rarely, back pain or chest pain may occur. Therefore, during treatment, blood pressure should be monitored.
Patients taking Agapurin SR 600 simultaneously with ciprofloxacin should be under constant medical supervision (see "Agapurin SR 600 and other medicines" below).
Patients taking pentoxifylline simultaneously with theophylline should be under constant medical supervision (see "Agapurin SR 600 and other medicines").

Agapurin SR 600 and other medicines

You should tell your doctor about all medicines you are currently taking or have recently taken, as well as any medicines you plan to take.
Agapurin SR 600 may enhance the effect of antihypertensive medicines (including ACE inhibitors) or other medicines that lower blood pressure (e.g., nitrates).
In patients treated with insulin or oral antidiabetic drugs, after administration of Agapurin SR 600, a decrease in blood glucose levels may occur. Therefore, diabetic patients should be under constant medical supervision.
In patients taking pentoxifylline simultaneously with vitamin K antagonists, cases of increased anticoagulant effect have been reported. When starting or modifying the dose of Agapurin SR 600 in these patients, close monitoring of anticoagulant activity is recommended.
Due to the increased risk of bleeding, caution should be exercised in patients taking pentoxifylline simultaneously with platelet aggregation inhibitors, such as clopidogrel, eptifibatide, tirofiban, epoprostenol, iloprost, abciximab, anagrelide, non-steroidal anti-inflammatory drugs other than selective COX-2 inhibitors, acetylsalicylic acid (aspirin) or lipoic acid, ticlopidine, dipyridamole.
In some patients, concomitant use of pentoxifylline and theophylline may increase theophylline levels in the blood and enhance the adverse effects associated with its use.
In some patients, concomitant use of pentoxifylline and ciprofloxacin may increase pentoxifylline levels in the serum. Therefore, an increase in the frequency and severity of adverse effects associated with concomitant use of these two active substances may occur.
Concomitant use of Agapurin SR 600 with cimetidine may increase pentoxifylline and its active metabolite levels in the blood.

Agapurin SR 600 with food and drink

See section 3.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, you should consult your doctor before taking this medicine.
This medicine is not recommended for use in pregnant or breastfeeding women.
In breastfeeding women, the doctor will decide whether the potential benefits outweigh the risks to the child.

Driving and using machines

This medicine does not affect the ability to drive or use machines.

3. How to take Agapurin SR 600

This medicine should always be taken as directed by your doctor. If you are unsure, consult your doctor or pharmacist.
The usual dose is one tablet once or twice a day.
Patients with low or variable blood pressure may require a special dosing schedule.
Dosing in patients with renal impairment
In patients with renal impairment (creatinine clearance <30 ml min), the doctor will reduce dose to 50-70% of usual recommended dose, depending on individual tolerance treatment.
Dosing in patients with liver impairment
In patients with severe liver failure, the dose should be reduced. The decision on the dose to be used is made by the treating doctor, depending on the degree of liver failure and individual tolerance to treatment.

Use in children and adolescents

There is no experience with the use of Agapurin SR 600 in children.
Method of administration
Tablets should be swallowed whole during or immediately after a meal, with a sufficient amount of water.

Use of a higher than recommended dose of Agapurin SR 600

In case of taking a higher dose of the medicine than recommended, you should immediately consult a doctor or pharmacist.
Initial symptoms may include nausea, dizziness, rapid heartbeat, hypotension, followed by fever, agitation, hot flashes, loss of consciousness, disappearance of reflexes, convulsions, and hematemesis (vomiting blood). Treatment of overdose is symptomatic. The patient may require intensive medical care in a hospital.
In case of overdose or accidental ingestion of the medicine by a child, you should immediately contact a doctor.

Missing a dose of Agapurin SR 600

In case of accidentally missing a dose of the medicine, you should take it as soon as possible. If the time for the next dose is approaching, you should take only that dose at the right time. Do not take a double dose to make up for the missed dose.

Stopping treatment with Agapurin SR 600

Without consulting a doctor, you should not stop taking the medicine.
If you have any further doubts about the use of this medicine, you should consult a doctor or pharmacist.

4. Possible side effects

Like all medicines, Agapurin SR 600 can cause side effects, although not everybody gets them.
You should immediately consult a doctor if you experience:

• symptoms of anaphylactic shock, disorientation, and fainting (due to circulatory disorders and a drop in blood pressure) or anaphylactic reactions, such as hives, swelling of the face, eyelids, lips, mouth, or difficulty breathing. These conditions can be life-threatening;
• retinal hemorrhage.

You should immediately consult a doctor if you experience a tendency to bruise and bleed, as these may be symptoms of thrombocytopenia (reduced platelet count). In such cases, during treatment with Agapurin SR 600, the patient's blood morphology should be regularly monitored.
Gastrointestinal side effects are dose-dependent and usually disappear after discontinuation of treatment.
Side effects may occur with the following frequency:
Common (occurring in 1 to 10 patients out of 100): nausea, vomiting, bloating, abdominal pain, diarrhea.
Uncommon (occurring in 1 to 10 patients out of 1000): dizziness, headache, blurred vision, hot flashes.
Rare (occurring in 1 to 10 patients out of 10,000): allergic skin reactions, flushing, itching, hives, increased sweating, cholestasis, increased liver enzyme activity, hypotension, tachycardia, palpitations, arrhythmias, angina pectoris, anxiety, sleep disorders, hallucinations, hypoglycemia, anaphylactic shock.
Very rare (occurring in less than 1 in 10,000 patients): aplastic anemia, thrombocytopenia, bleeding (e.g., into the skin, mucous membranes, stomach, intestines).
Unknown (frequency cannot be estimated from available data): anaphylactic reaction, pseudo-anaphylactic reaction, leukopenia or neutropenia, agitation, angioedema, rash, aseptic meningitis, gastrointestinal disorders, discomfort in the upper abdomen, feeling of fullness in the stomach, constipation, excessive salivation, decreased blood pressure, bronchospasm.

Reporting side effects

If you experience any side effects, including any side effects not listed in the leaflet, you should tell your doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Adverse Reaction Monitoring of Medicinal Products, Medical Devices, and Biocidal Products
Al. Jerozolimskie 181C
02-222 Warsaw
tel.: +48 22 49 21 301
fax: +48 22 49 21 309
website: https://smz.ezdrowie.gov.pl
By reporting side effects, you can help gather more information on the safety of the medicine.

5. How to store Agapurin SR 600

Store in a place out of sight and reach of children.
There are no special precautions for storage.
Do not use after the expiry date stated on the packaging. The expiry date refers to the last day of the specified month.
Medicines should not be disposed of via wastewater or household waste. You should ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.

6. Contents of the packaging and other information

What Agapurin SR 600 contains

The active substance of the medicine is pentoxifylline in a quantity of 600 mg.
The other ingredients are: hypromellose 2208/15000, povidone 30, talc, magnesium stearate; coating:
Sepifilm 752 white (hypromellose, microcrystalline cellulose, polyoxyethylene 40 stearate, titanium dioxide (E 171)), simethicone emulsion SE4, macrogol 6000.

What Agapurin SR 600 looks like and contents of the packaging

White or almost white, oval, biconvex tablets with a dividing line.
Pack size: 20, 50, or 100 prolonged-release tablets in blisters in a cardboard box.
For more detailed information, you should contact the marketing authorization holder or parallel importer.

Marketing authorization holder in Bulgaria, the country of export:

Zentiva k.s.
U Kabelovny 130
Dolní Měcholupy
102 37, Prague 10
Czech Republic

Manufacturer:

Saneca Pharmaceuticals a.s.
Nitrianska 100
92027 Hlohovec
Slovakia
Zentiva k.s.
U Kabelovny 130
Dolní Měcholupy
102 37, Prague 10
Czech Republic

Parallel importer:

Delfarma Sp. z o.o.
ul. Św. Teresy od Dzieciątka Jezus 111
91-222 Łódź

Repackaged by:

Delfarma Sp. z o.o.
ul. Św. Teresy od Dzieciątka Jezus 111
91-222 Łódź
Marketing authorization number in Bulgaria, the country of export: 20010389

Parallel import authorization number: 129/25

Date of leaflet approval: 07.04.2025

[Information about the trademark]